|
|
| Protection Sociale > Etude de marché sectorielle |
| UK Critical Illness and Income Protection 2006 |
|
|
|
|
€ 2 236,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Mai 2006 |
Taille du document : |
79 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Case or Care Management
130 pages | Octobre 2006 |
Case or Care Management |
55,00 €
|
| |
| |
Managed Care in Global Healthcare Markets
150 pages | Novembre 1998 |
Resulting from a desire to rid the economy of skyrocketing health inflation, the cost-controlling methods of managed care, pioneered by America's earliest HMO's, are providing the inspiration for |
795,00 €
|
| |
| |
Performance Ratio Benchmarking in UK Accident & Health Insurance 2007
18 pages | Septembre 2007 |
IntroductionThe report provides a detailed analysis of the performance ratios of the top 10 UK accident and health insurers.
It analyzes the loss, expense and combined ratios of these players and c |
1 356,00 €
|
| |
| |
Direct Life, Health and Medical Insurance Carriers in the US
40 pages | Septembre 2006 |
This is the replacement to IBISWorld's May 2006 edition of Direct Life, Health, and Medical Insurance Carriers in the US report.This report from IBISWorld provides a detailed analysis of the Direct Li |
550,00 €
|
| |
| |
Pay for Performance (P4P)
94 pages | Octobre 2006 |
Pay for Performance (P4P) |
47,00 €
|
| |
| |
Healthcare In Scotland
52 pages | Mai 2000 |
The Scottish Presentation Includes:- The Structure Of The NHS In Scotland- The Funding Of The NHS In Scotland- Distribution Of The NHS Budget In Scotland- Segmentation Of Expenditure - Total Capital E |
327,00 €
|
| |
| |
Pharmaceutical Pricing Strategies: Price optimization, reimbursement and regulation in Europe, US and Japan
240 pages | Avril 2005 |
Maximizing prices and securing reimbursement status for a product is increasing in importance, as pharmaceutical companies seek to ensure that they achieve a high return on investment from current and |
1 520,00 €
|
| |
| |
Indian Health Insurance
107 pages | Septembre 2007 |
Health insurance market in FY2007 is estimated to be USD659.1m registering a growth of 30% compared with FY2006.
In FY2006,the life insurance market occupied the major pie constituting 83.82% of th |
600,00 €
|
| |
| |
Health Insurance in Australia
41 pages | Août 2006 |
IBISWORLD INDUSTRY MARKET RESEARCH REPORTThis is the replacement for IBISWorld's August 2006 edition of Health Insurance in Australia report.Industry Market Research SynopsisThis Industry Market Resea |
515,00 €
|
| |
| |
2007 Worldwide Health & Medical Insurance Carriers Industry Report
104 pages | Janvier 2007 |
The Health & Medical Insurance Carriers Industry report features 2007 current and 2008 forecast estimates on the size of the industry (sales, establishments, employment) for the 47 largest world count |
160,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| UK Critical Illness and Income Protection 2006 |
|
|
Introduction
Examines the markets for Critical Illness and Income Protection in the UK, looking at the relative sizes of the markets and assessing the future of these protection products
Scope
Looks at the Income protection and Critical Illness markets in terms of new business, number of policies sold and distribution
Assesses the factors that have driven these markets to their current levels and forecasts premium income growth in the individual protection market
Provides action points for increasing future business of both IP and CII and assesses which of these product are likely to see growth in the long term
Highlights
Perceived complications in the IP market have led to both advisors and consumers overlooking these products. However as the CII market is hit by rising prices and negative publicity, advisors need to look to IP as an alternative product to fulfil customers' protection needs
Reasons to Purchase
Provides historic and forecast data for the UK individual protection market.
Utilizes in-depth primary research to provide the answers to how the markets have arrived at the point they have and what the future holds.
Identifies areas and product features where and where development is needed if these products are to continue to survive.
|
|
Introduction
Examines the markets for Critical Illness and Income Protection in the UK, looking at the relative sizes of the markets and assessing the future of these protection products
Scope
Looks at the Income protection and Critical Illness markets in terms of new business, number of policies sold and distribution
Assesses the factors that have driven these markets to their current levels and forecasts premium income growth in the individual protection market
Provides action points for increasing future business of both IP and CII and assesses which of these product are likely to see growth in the long term
Highlights
Perceived complications in the IP market have led to both advisors and consumers overlooking these products. However as the CII market is hit by rising prices and negative publicity, advisors need to look to IP as an alternative product to fulfil customers' protection needs
Reasons to Purchase
Provides historic and forecast data for the UK individual protection market.
Utilizes in-depth primary research to provide the answers to how the markets have arrived at the point they have and what the future holds.
Identifies areas and product features where and where development is needed if these products are to continue to survive.
|
|
|
PPLSEN
|
|
|
|
|
